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ABSTRACT 
Background: It is unknown whether indoles, metabolites of tryptophan that are derived 
entirely from bacterial metabolism in the gut, are associated with symptoms of 
depression and anxiety.  
Methods: Serum samples (baseline, 12 weeks) were drawn from participants (n=196) 
randomized to treatment with cognitive behavioral therapy (CBT), escitalopram, or 
duloxetine for major depressive disorder.  
Results: Baseline indoxyl sulfate abundance was positively correlated with severity of 
psychic anxiety and total anxiety and with resting state functional connectivity to a 
network that processes aversive stimuli (which includes the subcallosal cingulate cortex 
(SCC-FC), bilateral anterior insula, right anterior midcingulate cortex, and the right 
premotor areas). The relation between indoxyl sulfate and psychic anxiety was 
mediated only through the metabolite’s effect on the SCC-FC with the premotor area. 
Baseline indole abundances were unrelated to post-treatment outcome measures, 
which suggests that CBT and antidepressant medications relieve anxiety via 
mechanisms unrelated to gut microbiota.  
Conclusions: A peripheral gut microbiome-derived metabolite was associated with 
altered neural processing and with psychiatric symptom (anxiety) in humans, which 
provides further evidence that gut microbiome disruption can contribute to 
neuropsychiatric disorders that may require different therapeutic approaches.  
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INTRODUCTION  
The gut microbiota impacts numerous aspects of human health and disease (1), 
including neuropsychiatric disorders. The “microbiota–gut–brain axis” refers to a 
bidirectional communication pathway that connects the central nervous system (CNS), 
the gut, and the microbial community that inhabits the gastrointestinal tract (2).  Within 
this axis, the gut microbiota modulates central processes through the activation of 
neuronal pathways (e.g., the vagus nerve) as well as through the production of 
microbial metabolites and immune mediators that can trigger changes in 
neurotransmission, neuroinflammation, and behavior (3-6).  
 
Disruptions to the gut microbiome have been correlated with several neurological 
disorders, including Parkinson’s disease, autism spectrum disorder, schizophrenia, and 
major depressive disorder (MDD) (7-10), though the specific mechanisms that underlie 
the role of the gut microbiota in these diseases is not fully understood. However, 
research in preclinical rodent models shows that the gut microbiota is sufficient to alter 
host behavior, as shown by the increase in anxiety- and depressive-like behaviors in 
rodents after fecal microbiota transfer from humans with depression relative to those 
that received transfer of fecal microbiota from demographic controls (11-12). Further, 
transferred microbes resulted in altered metabolic states in the recipient mice that 
displayed depressive-like symptoms (12). These data implicate the gut microbiota as 
direct contributors to behaviors associated with depression and anxiety through their 
metabolic effects. In this study, we explore gut microbiota-associated tryptophan 
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metabolism and correlate levels of metabolites to clinical symptoms and severity of 
depression and anxiety in humans. 
 
Tryptophan is an essential amino acid that can be metabolized in the gastrointestinal 
tract via the serotonin, kynurenine, and indole metabolic pathways (Figure 1), which 
have been associated with human maladies including autoimmunity, inflammatory 
diseases, metabolic syndrome, and neurological diseases including depression and 
anxiety disorders (13,14). Strikingly, the gut microbiota is exclusively responsible for the 
conversion of tryptophan in the indole pathway, as there are no detectable levels of 
indole or indole derivatives in gnotobiotic mice that lack a gut microbiome (15). Analysis 
of biosynthetic pathways found that the genes necessary to make indole and indole 
derivatives, such as indole-3-propionic acid (IPA), indole-3-acetic acid (IAA), and indole-
3-lactic acid (ILA), are found exclusively in the gut microbiome but not in mammalian 
genomes (13) (Figure 1). These indoles can have important immunomodulatory effects 
and are potent agonists for aryl hydrocarbon receptors (16) (AHRs), which regulate host 
immunity and barrier function at mucosal sites (17).  
 
Indole derivatives can also affect immune status in the brain, as some indole derivatives 
(e.g., IPA and IAA) have anti-inflammatory effects on neurodegenerative diseases in the 
experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis 
(18,19) as well as in a cell line model of Alzheimer’s disease (20). Other indole 
derivatives can be further metabolized by host processes into molecules that may be 
harmful to human health. Specifically, indole can be sulfonated in the liver into uremic 
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toxin indoxyl sulfate (IS), which crosses the blood-brain barrier (21) (Figure 1). IS, which 
is normally cleared via the kidneys and excreted in the urine, is associated with 
cardiovascular disease in patients who have chronic kidney disease via induction of 
oxidative stress in endothelial cells (22), and peripheral IS concentrations are 
associated with diminished cognitive function in renal dialysis patients (23). 
 
IS is also associated with both neurodevelopmental and neurodegenerative diseases, 
as levels of IS are increased in patients who have an autism spectrum disorder (24) or 
Parkinson’s disease (25). Although the mechanistic role of IS in these diseases is 
unknown, IS increases levels of oxidative stress and pro-inflammatory cytokine 
signaling in astrocytes and mixed glial cells during in vitro administration (26), which 
suggests that inflammation and reactive oxygen species may be involved. Further, IS 
has been associated with behavioral defects in preclinical models of anxiety and 
depression. The administration of IS into rodents’ drinking water results in increased 
concentrations of IS in the brain and increased blood-brain barrier permeability in an 
AHR-dependent manner, with accompanying increases in anxiety and cognitive deficits 
(27,28). Monocolonization experiments with indole-producing Escherichia coli and 
isogenic mutants have shown that indole production by gut bacteria is sufficient to drive 
increases in anxiety- and depressive-like behavior in rats (29).  
 
Taken together, the preclinical and clinical data indicate that indole derivatives provide 
excellent models to study the microbiota-gut-brain axis given their connection to central 
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immune regulators (i.e., AHR), their link to human neurological diseases, and the 
exclusivity of indole production to gut microbes.  
 
To date, the effects of peripheral metabolic concentrations on neural functioning have 
received little study, likely due to the paucity of datasets that contain concurrently 
collected metabolomic and neuroimaging measures. Such research is crucial for 
determining how changes in peripheral systems may yield alterations in brain function 
that can produce clinically relevant symptoms such as depression, anxiety, or cognitive 
impairment.  
 
Using blood samples stored from the Prediction of Remission in Depression to 
Individual and Combined Treatments (PReDICT) study, which was a large study of 
treatment-naïve patients with MDD, we measured levels of four indole derivatives (IPA, 
IAA, ILA, IS) to address the following questions: 
1. Do levels of indoles and their ratios at baseline prior to treatment correlate with 
depression and anxiety severity at baseline? 
2. Do levels of indoles and their ratios at baseline correlate with specific individual 
symptoms of depression? 
3. Can symptom change after treatment with duloxetine, escitalopram, or cognitive 
behavioral therapy (CBT) be predicted by baseline levels of indoles, and does 
symptom change correlate with changes in levels of indoles after treatment?  
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4. Are there relationships between baseline peripheral metabolic concentrations of 
indoles and brain resting state functional connectivity as determined using 
functional Magnetic Resonance Imaging (fMRI).  
 
MATERIALS AND METHODS  
Study Design 
The PReDICT study protocol (30), clinical results (31) and initial neuroimaging analyses 
(32) have been published previously. The study was conducted through the Mood and 
Anxiety Disorders Program of Emory University from 2007-2013. The study was 
approved by Emory s Institutional Review Board. All patients provided written informed 
consent to participate. 
 
PReDICT was designed to identify predictors and moderators of outcomes to three 
randomly assigned first-line treatments for MDD: duloxetine, escitalopram, or CBT. The 
study enrolled treatment-naïve adult outpatients, aged 18–65 years, who had current 
MDD without psychotic symptoms. To be eligible for randomization, participants had to 
score ≥18 at screening and ≥15 at baseline on the HAM-D. Key exclusion criteria 
included the presence of any medically significant or unstable medication condition that 
could impact study participation, safety, or data interpretation; any current eating 
disorder, obsessive-compulsive disorder, or any current substance abuse or 
dependence. Treatment was provided for 12 weeks with duloxetine (30-60 mg/day), 
escitalopram (10-20 mg/day), or CBT (16 individual one-hour sessions). 
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Symptom Assessments 
At the baseline visit, participants were assessed by trained interviewers using the HAM-
D and the HAM-A. The HAM-A is a 14-item measure that consists of two subscales, 
“psychic anxiety” (items 1–6 and 14), and “somatic anxiety” (items 7–13) (33). Psychic 
anxiety consists of the symptoms of anxious mood, tension, fears, depressed mood, 
insomnia, impaired concentration, and restlessness. Somatic anxiety consists of 
physical symptoms associated with the muscular, sensory, cardiovascular, respiratory, 
gastrointestinal, genitourinary, and autonomic systems. Participants also completed the 
QIDS-SR, which assesses the nine diagnostic symptom criteria for MDD (34). The 
HAM-D, HAM-A, and QIDS-SR were repeated at the Week 12 visit.  
 
Blood Sampling 
Participants who met all eligibility criteria at the baseline visit underwent an antecubital 
phlebotomy, without regard for time of day or fasting/fed status. Sampling was repeated 
at the week 12 visit.  Collected samples were allowed to clot for 20 minutes and then 
centrifuged at 4°C to separate the serum, which was frozen at -80°C until being thawed 
for the current analyses.  
 
Neuroimaging 
To explore associations between indole metabolites and brain function, we used the 
resting state fMRI scans collected during the week prior to baseline, the details of which 
have previously been published (32).  Briefly, eyes-open scanning was performed for 
7.4 minutes in a 3-T Siemens TIM Trio (Siemens Medical Systems, Erlangen, 
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Germany). Echo planar images were corrected for motion and slice-time acquisition. 
Scans with head motion >2 mm in any direction were removed from the analysis. The 
nuisance regressors, including head motion parameters, signal from the ventricle mask, 
and signal from a region of local white matter, were cleaned. Subsequently, data were 
applied a band-pass filter and smoothed using an isotropic Gaussian kernel of 8 mm full 
width at half maximum. The imaging anatomical and functional data sets were co-
registered and normalized to standard Montreal Neurological Institute (MNI) 1-mm voxel 
space. Image analysis was conducted using Analysis of Functional NeuroImages 
(AFNI) (35,36) 3dvolreg. Consistent with our prior analyses (32), we used a region-of-
interest seed-based approach to assess the resting state functional connectivity (RSFC) 
of the SCC. The SCC volume was defined using the Harvard-Oxford Atlas (37), and the 
SCC was thresholded at 50% probability centered on MNI coordinates 66, 24, –11. The 
seeds comprised two 5-mm radius spheres, with a final volume of 485 mL each. 
Utilizing 3dNetCorr (38), the mean time course of the bilateral seed was correlated 
voxel-wise with the rest of the brain. The voxelwise correlation coefficients were then z-
scored by calculating the inverse hyperbolic tangent, yielding the seed-based RSFC 
maps for analysis. 
 
Metabolomics Data Acquisition  
Metabolomics data focused on primary and polar metabolites using gas 
chromatography – time of flight mass spectrometry (39). Briefly, 30 μl of plasma was 
extracted at -20ºC with 1 mL degassed isopropanol/acetonitrile/water (3/3/2). Extracts 
were dried down, cleaned from triacylglycerides using acetonitrile/water (1/1), and 
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derivatized with methoxyamine and trimethylsilylation. Samples (0.5 μL) were injected at 
250ºC to a 30 m rtx5-SilMS column, ramped from 50-300ºC at 15ºC/min, and analyzed 
by -70 eV electron ionization at 17 spectra/s. Raw data were deconvoluted and 
processed using ChromaTOF vs. 4.1 and uploaded to the UC Davis BinBase database 
(40) for data curation and compound identification (41). Result data were normalized by 
SERRF software to correct for drift or batch effects (42).  
 
Statistical Analyses 
Indole abundance and ratios of each indole pair were included in all analyses. In order 
to investigate the role of indoles in depression and anxiety symptomology at baseline, 
partial Spearman rank correlations were conducted between the baseline 
abundance/ratio of each indole and HAM-D 17-item total score, HAM-A total score, 
HAM-A Psychic and Somatic subscores, QIDS-SR 16-item total score, and each 
individual QIDS-SR item after accounting for age, sex, and body mass index (BMI). 
Spearman correlations were also conducted between baseline indole abundance/ratio 
and participant demographic factors (age, BMI, height, and weight).  Additionally, sex 
differences in baseline indole abundance/ratio were tested using Mann-Whitney U tests 
and fold changes in median abundance/ratio between groups. 
 
To investigate the potential effects of treatment on indoles, changes in indole 
abundance from pre- to post-treatment were tested using Wilcoxon signed-rank tests 
and fold changes. Partial Spearman rank correlations were conducted between post-
treatment indole abundance/ratio and post-treatment HAM-D 17-item total score, HAM-
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A total score, and HAM-A Psychic and Somatic subscores, QIDS-SR 16-item total 
score, and each individual QIDS-SR item, after accounting for age, sex, and baseline 
BMI. The same analyses were also conducted with change from pre- to post-treatment 
scores of all psychiatric variables, and also with fold changes from pre- to post-
treatment for each indole. Additionally, differences in indole post-treatment 
abundance/ratio and fold change were investigated between each pair of treatment 
response outcome groups (31) (treatment failure; partial response; response; remission) 
by conducting Mann-Whitney U tests. This analysis was also repeated with baseline 
indole abundances/ratios to investigate whether baseline levels of indoles may be 
associated with treatment outcome. All reported p-values were adjusted for multiple 
comparisons using the Holm method.  
 
Neuroimaging analyses were conducted using AFNI (35) and jamovi (www.jamovi.org). 
Of 122 participants who had an adequate quality of resting-state fMRI data (32), 80 had 
metabolomic measurements and clinical scores. Voxel-wise linear regression analyses 
were performed to examine the relationship between SCC-FC and IS or psychic anxiety 
scores (uncorrected p < 0.005 and > 250 voxels cluster size). A conjunction analysis 
identified overlapping areas between the SCC-FC of IS and the SCC-FC of psychic 
anxiety scores. Subsequently, mediation analyses were performed using the Medmod 
module (43) in jamovi. Three regions identified by the whole brain linear regression 
analysis between SCC-FC and IS were used for the mediation analysis. We explored 
each region, and combinations of the three regions, in the mediation models. For each 
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model, the direct and indirect effects were estimated using bootstrapping with 5000 
samples. 
 
RESULTS 
Of the 344 patients randomized in PReDICT, 196 had metabolomic measures available 
for analysis at baseline and 127 were available at week 12. The demographic and 
clinical characteristics of the 196 participants are presented in Table 1. 
 
Baseline Associations 
Associations of indole metabolites with demographic variables 
Supplemental Figure 1 shows a heat map of correlations between baseline indole 
abundance/ratio and participant demographic variables. Abundance of ILA was 
positively associated with age, height, and weight (all rs > 0.18, all ps < 0.040). The 
ratios of IAA/ILA (negative associations) and IS/ILA (positive associations) were also 
significantly associated with height and weight (all ps < 0.034). For sex differences, 
abundance of IAA (Fold Changes (FC) = 1.19, p = 0.039) and ILA (FC = 1.37, p < 10-9), 
and ratios of ILA/IPA (FC = 1.40, p = 0.004) and ILA/IS (FC = 1.16, p = 0.013) were all 
found to be significantly higher in men than in women. 
 
Associations of indole metabolites with depression and anxiety 
Figure 2 shows a heat map of correlations between baseline indole abundance/ratio 
and baseline levels of the 17-item Hamilton Depression Rating Scale (HAM-D) (44) total 
score, Hamilton Anxiety Rating Scale (HAM-A) (45) total score, and HAM-A psychic and 
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somatic subscores. Greater abundance of IS was associated with higher scores on the 
HAM-D 17-item total score (r = 0.21, p = 0.018), HAM-A total score (r = 0.26, p = 0.002), 
and HAM-A psychic subscore (r = 0.31, p = 0.0001), but not on the HAM-A somatic 
subscore. Additionally, the ratios of ILA/IS and IPA/IS were negatively correlated with 
HAM-A total and psychic scores (all rs > -0.20, all ps < 0.033), for which a negative 
correlation indicates that increasingly severe symptoms are associated with a relative 
increase in IS and/or a relative decrease in ILA or IPA. Additionally, IPA/IS was 
negatively correlated with HAM-D total score (r = -0.24, p = 0.001). 
 
Associations of indole metabolites with individual symptoms of depression 
Correlations between Quick Inventory of Depressive Symptoms – Self-Report (QIDS-
SR) (34) items, and total scores and indole abundances/ratios are presented in Figure 
3. Of note, IS positively correlated with items 4 (hypersomnia; r = 0.22, p = 0.016) and 6 
(decreased appetite; r = 0.20, p = 0.034), and the IPA/IS ratio negatively correlated with 
QIDS-SR total score (r = -0.21, p = 0.027).  
 
Treatment Effects 
Compound abundance significantly increased from pre- to post-treatment for ILA (FC = 
1.05, p = 0.006), but not for any other compound/ratio (all ps > 0.12). This indicates that 
the treatments had limited overall effect on indole composition and levels. 
 
For post-treatment indole abundances and ratios, there were significant correlations 
between IAA/IS and QIDS-SR item 15 (feeling slowed down; r = 0.30, p = 0.007). 
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Additionally, post-treatment ILA abundance was significantly higher in men than in 
women (FC = 1.24, p = 0.00001), as was the ILA/IPA ratio (FC = 1.54, p = 0.002). 
Conversely, the IPA/IS ratio was lower in men than in women (FC = 0.80, p = 0.048). 
No other significant post-treatment effects were observed. 
 
For fold changes, change in IAA/IS ratio correlated with post-treatment scores of QIDS-
SR item 5 (feeling sad; r = 0.27, p = 0.032). No significant associations were observed 
when correlating indole fold changes with any other post-treatment scores, or with 
change in depression/anxiety scores (all ps > 0.10).  Additionally, no sex differences 
were observed for fold changes (all ps > 0.07), and no differences in fold changes were 
observed between response outcome groups (all ps > 0.12).  
 
Baseline levels of indoles and their ratios did not significantly correlate with changes in 
symptoms for any measure or item (all rs < 0.15, ps > 0.59). Comparison of categorical 
response outcomes also showed no meaningful differences in baseline indole 
abundances or ratios. These analyses indicate that pre-treatment indole compound 
abundances are not predictive of eventual treatment outcomes.  
 
Associations of indole metabolites with brain resting state functional connectivity 
Relationships of Subcallosal Cingulate Cortex – Functional Connectivity (SCC-FC) with 
IS and with psychic anxiety scores are shown in Figure 4. IS abundance was positively 
correlated with SCC-FC with the bilateral anterior insula, anterior midcingulate cortex 
(aMCC), supplementary motor area (SMA), and right premotor area (Figure 4A). 
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Psychic anxiety scores showed a significant positive correlation with SCC-FC with the 
left aMCC, right precuneus, and right premotor area; there was a negative correlation 
with SCC-FC with the ventromedial prefrontal cortex, right orbitofrontal, and left 
Brodmann Area 47 (Figure 4B). The conjunction analysis identified one overlapping 
area: the right premotor region (Figure 4C). 
 
The mediation analyses explored whether the association of IS with psychic anxiety was 
mediated through its effects on SCC-FC. Figure 5A shows the overall association 
between IS and psychic anxiety (z = 1.976, p = 0.048). Figure 5B shows that the 
identified overlapping area in the SCC-FC analyses – the right premotor region – 
mediated the association between IS and psychic anxiety (indirect pathway: z = 2.138, p 
= 0.033). Because our whole brain SCC-FC analyses had also found IS concentrations 
to be significantly associated with two other regions previously identified in 
neuroimaging studies of anxiety (the right anterior insula and the aMCC, Figure 4A), we 
conducted further mediation analyses incorporating these two regions along with the 
right premotor region. Even though the three regions were highly correlated with each 
other in their functional connectivity to SCC (Figure 5C), only the right premotor region 
mediated the relationship between IS and psychic anxiety scores when all three regions 
were included in the model (Figure 5D, indirect pathway: z = 1.991, p = 0.046). 
 
DISCUSSION 
Increasing evidence suggests that gut bacteria can complement human metabolism, 
and that together they define the metabolome comprised of the collection of small 
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molecules in blood and in different organs. Bacteria can further metabolize compounds 
available through human metabolism, food-intake, and/or human ingestion of chemicals. 
Also, humans can further metabolize compounds produced by bacteria, which results in 
human-bacteria co-metabolism and the production of a large number of chemicals that 
can impact human health, including brain function. Examples include the metabolism of 
cholesterol and its clearance mediated by bacteria, which can produce secondary bile 
acids that we recently implicated in the pathogenesis of Alzheimer’s disease (46,47). 
Several compounds produced from the metabolism of phospholipids and choline by gut 
bacteria lead to compounds like trimethylamine N-oxide, which have been implicated in 
cardiovascular diabetes and CNS disease (48,49). 
  
Indoles represent a class of gut bacterially-derived compounds that are produced from 
tryptophan, an essential amino acid that can also be converted (through separate 
pathways) into tryptamine, serotonin, skatol, and melatonin, among other metabolites 
involved in CNS functioning and diseases. Mounting evidence suggests that indoles 
derived from gut bacterial metabolism exert significant biological effects and may 
contribute to the etiology of cardiovascular, metabolic, and psychiatric diseases. To 
date, research in this area has been mainly limited to experimental studies in model 
systems.  
 
In this investigation, we interrogated levels of four indoles produced by gut bacteria and 
their relationship to anxiety and depression severity and response to treatment. At 
baseline, IS abundance was found to positively correlate with severity of Psychic 
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Anxiety and total anxiety. IPA seems protective, as noted earlier, indicating that indoles, 
as a class, can have mixed effects on neuropsychiatric health. Different strains of 
bacteria can lead to the production of different indoles; for example, tryptophanase-
producing bacteria produce toxic IS while Clostridium sporogenes and other bacterial 
strains produce protective IPA (50,51). Notably, IS levels did not meaningfully change 
with treatment, and changes in IS were not correlated with improvement in depression 
or anxiety measures. This suggests that gut microbiome composition and activity might 
be modulated as an approach for developing additional classes of therapies effective in 
the treatment of anxiety and depression.   
 
This association between IS and anxiety seems to be mediated by the impact of IS on 
the functional connectivity between the SCC and the right premotor region. IS 
abundances were also associated with activation of a well-established network for the 
processing and control of emotionally salient, particularly aversive, stimuli, comprising 
the anterior insula and aMCC. Taken together, these results suggest that the co-
metabolism of tryptophan by certain gut microbiota that result in the production of IS, 
which can induce anxiety through the activation of established brain networks, and that 
existing treatments do not specifically resolve this pathogenetic process when they lead 
to clinical improvement.  
 
The neuroimaging analyses indicate that the effect of IS on psychic anxiety symptoms is 
mediated through the functional connectivity of the SCC with the premotor cortex, as 
part of a network involved in processing emotionally salient stimuli. The anterior insula, 
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aMCC, and supplementary motor area form a network that is involved in the attention 
to, interpretation of, and control of emotional responses (52-56). The premotor cortex is 
functionally and structurally connected to the SMA and the aMCC, which act together in 
the preparation and readiness for voluntary movement in response to internal and 
external stimuli (57), and the aMCC is a site of integration for the processing of pain and 
motor control (58). Outputs from this network include projections to the spinal cord and 
adrenal medulla (59), which may contribute to the sympathetic arousal and heightened 
cortisol release under situations of psychic stress.  
 
Although the activity of the premotor cortex has not been a major focus in studies of 
anxiety and depression, Pierson and colleagues (60), using the electroencephalography 
measure of contingent negative variation (which localizes to the premotor cortex (61)), 
demonstrated abnormal activation of this region in anxious MDD patients compared to 
MDD patients with psychomotor retardation. Ma and colleagues (62) found that patients 
with generalized anxiety disorder have increased resting state functional connectivity 
between the habenula and right premotor cortex. Others have found abnormal premotor 
function in social anxiety disorder (63).  
 
Our finding of an association between IS and activation of the insula bilaterally is 
consistent with the insula’s known involvement in processes relevant to anxiety, 
including emotional salience (64), empathy for others’ pain, and processing of 
uncertainty (55,65-67). In contrast, we did not find an association between IS 
abundances and somatic anxiety scores, nor was there an association of IS 
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abundances with functional connectivity of the SCC-posterior insula, the insular region 
involved in sensorimotor integration. This reveals the specificity of the IS-anterior insula 
association for psychic anxiety.  
 
Conceptualizing psychic anxiety as a chronic aversive stimulus akin to long-term pain 
may explain the positive correlation between higher IS levels and the QIDS-SR loss of 
appetite item.  In mice, inflammatory pain is inhibited in the presence of hunger, 
mediated by neuropeptide Y signaling in the parabrachial nucleus (68). The association 
of higher IS concentrations with both reduction in appetite and increased connectivity 
between brain regions involved in pain processing (anterior insula and aMCC) may 
indicate that the symptom of low appetite reflects a compensatory response to this 
chronic anxiety-type pain. 
 
Limitations of this study include the absence of a healthy control comparison group. We 
lacked fecal samples we could analyze which would allow for a more direct correlation 
between specific gut microbiome species and the IS measures. We could not determine 
whether IS is the etiological agent of the anxiety because IS also acts to reduce the 
integrity of the blood brain barrier (28), thereby creating the possibility that CNS 
penetration by an alternative molecule in the periphery is responsible for the observed 
association between anxiety and IS.  
 
Taken together, our results indicate that increases in IS lead to the activation of an 
established network that is involved in the processing and control of aversive stimuli, but 
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that the conscious experience of anxiety depends upon the degree of IS-related 
activation of SCC-right premotor cortex functional connectivity. The absence of an 
association between psychic anxiety scores and anterior insula/aMCC SCC-FC (Figure 
4B) may indicate that although IS activates this control network in all patients, it is only 
when network function is inadequate that psychic anxiety ensues in conjunction with 
premotor activation in preparation for action (69). These analyses reveal the potential of 
integrated peripheral metabolomic-neuroimaging analyses to reveal mechanistic 
pathways that are associated with neuropsychiatric symptoms, especially for 
characterizing the pathological impact of specific gut microbiome-derived metabolites. 
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FIGURE LEGENDS 
 
Figure 1. Tryptophan human gut bacterial co-metabolism leading to production of 
indoles including IPA, IAA, ILA and IS. 
Abbreviations: 3-HAA: 3-Hydroxyanthranilic Acid; 3H-KYN: 3-Hyroxykynurenine; 5-HTP: 
5-hydroxytryptophan; AAAD: Aromatic Amino Acid Decarboxylase; AANAT: 
Aralkylamine N-Acetyltransferase; acdA: acyl-CoA dehydrogenase; AraT: Aromatic 
Amino Acid Aminotransferase; ASMT: Acetylserotonin O-Methyltransferase; fldBC: 
phenyllactate dehydratase; fldH: phenyllactate dehydrogenase; IA: Indole Acrylic acid; 
IAA: Indole Acetic Acid; IAAld, indole-3-Acetaldehyde; IAld: Indole-3-Aldehyde; IAM: 
indole-3-Acetamide; IDO: Indolamine 2,3-Dioxygenase; ILA: Indole-3-Lactic Acid; IPA: 
Indole-3-Propionic Acid; IPYA: Indole-3-Pyruvate; KAT: Kynurenine aminotransferase; 
KMO: Kynurenine 3-Monooxygenase; KYNU: Kynureninase; MAO: Monoamine 
Oxidase; NAD: Nicotinamide Adenine Dinucleotide; porB, C: pyruvate : ferredoxin 
oxidoreductase B and C; TDO: Tryptophan 2,3-Dioxygenase; TMO: Tryptophan 2-
Monooxygenase; TNA: Tryptophanase; TpH: Tryptophan Hydroxylase; TrD: Tryptophan 
Decarboxylase. 
 
Figure 2. Heat map of partial Spearman rank correlations between baseline indole 
abundance/ratio and Hamilton Anxiety scores and Hamilton Depression scores, after 
accounting for age, sex, and BMI. 
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Figure 3. Heat map of partial Spearman rank correlations between baseline indole 
abundance/ratio and QIDS-SR items and total score, after accounting for age, sex, and 
BMI. 
Abbreviations: QIDS-SR: 16-item Quick Inventory of Depressive Symptomatology – 
Self-Rated. 
 
Figure 4. Resting state functional connectivity of subcallosal cingulate cortex (SCC) 
associations with peripheral indoxyl sulfate abundances and psychic anxiety scores. 
A: SCC functionally connected regions showing a significant correlation with 
indoxyl sulfate abundances. Orange circles identify regions incorporated into the 
mediation models. 
B: SCC functionally connected regions showing a significant correlation with 
psychic anxiety scores. Green circle identifies right premotor region. 
C: Conjunction analysis: SCC functionally connected region showing a significant 
correlation with both indoxyl sulfate abundances and psychic anxiety scores. The 
red circle indicates the only region to emerge in this analysis, the right premotor 
region. 
Abbreviations: HAMPSY: Psychic anxiety subscore of the Hamilton Anxiety Rating 
Scale. SCC-FC: subcallosal cingulate cortex functional connectivity 
 
Figure 5. The impact of indoxyl sulfate on psychic anxiety scores is mediated by its 
effects on the resting state functional connectivity between the subcallosal cingulate 
cortex and the right premotor region. 
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A. Association between indoxyl sulfate and psychic anxiety scores.  
B. Mediation model incorporating the overlapping area, right premotor region, 
indicating that the effect of indoxyl sulfate on psychic anxiety is mediated via 
its effects on the functional connectivity between the SCC and right premotor 
region.  
C. Significant SCC-FC correlations between the right anterior insula, right 
anterior midcingulate cortex, and right premotor region, which were included 
in the mediation model shown in D. 
D. Full mediation model incorporating the three regions showing significant SCC-
FC correlations with indoxyl sulfate abundances. Although indoxyl sulfate is 
significantly correlated with all three regions, only the pathway through the 
right premotor region significantly mediates indoxyl sulfate’s effect on psychic 
anxiety.  
Note: Black lines indicate significant associations within the model; grey lines are 
insignificant associations. Red line indicates significant mediation of indoxyl sulfate on 
psychic anxiety through the indirect pathway of right premotor SCC-FC.   
Abbreviations: HAMPSY: Psychic anxiety subscore of the Hamilton Anxiety Rating 
Scale. SCC-FC: subcallosal cingulate cortex functional connectivity. 
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Table 1. Subject demographic and clinical characteristics 
Variable N (%) (N=196) 
Sex (Female) 122 (62.2%) 
Race  
   White 73 (37.2%) 
   Native American 58 (29.6%) 
   Black 38 (19.4%) 
   Asian 2 (1.0%) 
   Multiracial 14 (7.1%) 
   Unknown/Not Reported 11 (5.6%) 
Hispanic ethnicity (%) 77 (39.3%) 
 Mean (SD) 
Age (years) 39.11 (11.77) 
Body mass index 28.73 (6.27) 
HAM-D 17-item total score (baseline) 19.76 (3.77) 
QIDS-SR total score (baseline) 14.27 (3.83) 
HAM-A total score (baseline) 16.28 (5.37) 
HAM-A psychic anxiety subscale score (baseline) 10.79 (2.69) 
HAM-A somatic anxiety subscale score (baseline) 5.48 (3.73) 
 
Abbreviations: HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression 
Rating Scale; QIDS-SR: Quick Inventory of Depressive Symptomatology, Self-report. 
 
  
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 9, 2020. ; https://doi.org/10.1101/2020.12.08.388942doi: bioRxiv preprint 
38 
 
Figure 1 
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Figure 2.  
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Figure 3.  
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Figure 4.  
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Figure 5.  
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